Core Viewpoint - Molecular Partners AG is advancing its leadership by nominating Clare Fisher to the Board of Directors, aiming to enhance its strategic capabilities in the biotech sector [3][4]. Group 1: Annual General Meeting Details - The Annual General Meeting is scheduled for April 14, 2026, at 9:00 am CET in Schlieren, Switzerland [2]. - The meeting will include the election of Clare Fisher as a new Board member [1]. Group 2: Clare Fisher's Background - Clare Fisher has over 20 years of experience in the healthcare sector, focusing on business development and mergers and acquisitions [4]. - She currently serves as SVP for Global Business Development and M&A at BeOne Medicines and has held senior roles at various biotech companies [4]. Group 3: Board Member Changes - Current Board member Steven H. Holtzman will not seek re-election after 12 years of service [5]. - The company expressed gratitude for Holtzman's contributions, highlighting his role in securing partnerships and navigating challenges [6]. Group 4: Company Overview - Molecular Partners AG specializes in developing DARPin therapeutics, targeting medical challenges that other treatments cannot address [8]. - The company has a pipeline of innovative therapeutics and collaborates with leading pharmaceutical companies and academic institutions [9]. Group 5: Financial Calendar - Key upcoming financial events include the Interim Management Statement for Q1 2026 on May 12, 2026, and the Half-year results on August 25, 2026 [7].

Core Insights - Molecular Partners AG is making significant advancements in targeted alpha radiotherapy, particularly with its first Radio-DARPin candidate, MP0712, which is entering clinical development for lung cancer treatment [2][3] - The company has a strong financial position with cash reserves of CHF 93.1 million, sufficient to fund operations until 2028 [5][24] Research & Development Highlights - The Phase 1/2a trial for MP0712, targeting DLL3, has commenced, with initial clinical data expected in 2026 [3][5] - MP0726, another Radio-DARPin candidate targeting mesothelin (MSLN), is progressing towards first-in-human imaging [7] - A development agreement with Eckert & Ziegler has been signed to enable proprietary Radio-DARPin candidates with various isotopes [5][8] - The company is also advancing MP0317, a tumor-localized CD40 agonist, in a Phase 2 study for cholangiocarcinoma [11][12] - MP0533, a tetra-specific T cell engager for acute myeloid leukemia (AML), is in a Phase 1/2a trial, with updates expected in H1 2026 [13][15] Financial Highlights - In 2025, the company reported no revenue, with total operating expenses of CHF 58.1 million, leading to a net loss of CHF 61.7 million [21][22] - Cash and cash equivalents decreased by CHF 56.3 million from the previous year, totaling CHF 93.1 million as of December 31, 2025 [23][24] - The company anticipates total operating expenses of CHF 45-55 million for 2026 [27] Corporate Governance & Leadership - Martin Steegmaier has been appointed as Chief Scientific Officer, bringing extensive experience in oncology drug development [19] - A scientific advisory board has been formed to guide the development of targeted radiotherapeutics [9]

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, a new class of custom-built protein drugs [5] - The company will present at two upcoming investor conferences and release its full-year 2025 financial report on March 12, 2026 [1][4] Conference Details - Molecular Partners will participate in the TD Cowen 46th Annual Health Care Conference in Boston, MA from March 2-4, 2026, with CEO Patrick Amstutz scheduled for a fireside chat on March 2 [2] - The company will also attend the Leerink Partners Global Healthcare Conference in Miami, FL from March 9-11, 2026, where CEO Patrick Amstutz will have a fireside chat on March 9 [3] Financial Reporting - The full-year 2025 financial results will be announced on March 12, 2026, at 4:00 PM EDT [4]

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Clinical Development - The data from five evaluable patients show favorable tumor uptake of MP0712 with limited uptake in healthy tissues, supporting its therapeutic potential [2][3] - The biodistribution and dosimetry data validate the ongoing U.S. Phase 1/2a study of MP0712, which aims to assess safety and determine a recommended phase 2 dose [4][5] Presentation Details - Two posters and an oral presentation were made at the congress, highlighting the specific tumor accumulation and dosimetry data that support the clinical development of MP0712 [5][7] - The oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was scheduled for January 31, 2026, focusing on the progress of MP0712 [7] Future Outlook - Initial clinical data from the Phase 1/2a study of MP0712 is expected in 2026, with the company planning to share safety and activity data as the study progresses [4][5] - The company aims to establish itself as a leader in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4]

Company Overview - Molecular Partners is a clinical-stage biotech company founded in 2004, with operations and listings in Switzerland (SIX, 2014) and the US (Nasdaq, 2021)[12] - The company is financed with approximately USD 116 million / CHF 93 million to reach upcoming value inflection points[12] - Molecular Partners focuses on oncology with differentiated assets like MP0712 (targeted radiotherapy) and MP0533 (next-gen immune cell engagers)[12] Radio-DARPin Therapeutics (RDT) - The company is developing Radio-DARPin therapeutics, which are designed for precise delivery of potent radio-isotopes to tumors[26, 27] - Molecular Partners has a global partnership with Orano Med to develop 212Pb Radio-DARPin therapeutics, with a 50:50 cost and share split for 4 programs[33, 36] - MP0712, a 212Pb x DLL3 Radio-DARPin, is in Phase 1/2a clinical trials in the US for small cell lung cancer (SCLC) and other neuroendocrine cancers (NECs), with early data expected in 2026[43, 77] - Preclinical data for MP0712 shows high tumor accumulation (Tumor > Kidney) and reduction of established tumors in mice[51] - MP0726, a 212Pb x MSLN Radio-DARPin, is being developed for ovarian cancer and is progressing towards first-in-human (FIH) imaging[86, 94] Other Pipeline Programs - MP0317, a FAP-localized CD40 agonist, is in a Phase 2 combo study in advanced biliary tract cancer, with interim analysis expected by YE 2027[104, 117, 123] - MP0533, a tetra-specific T-cell engager for AML, is in Phase 1/2a, with decisional data expected in H1 2026[124] - The company is developing Switch-DARPin platform for next-generation T cell engagers, with a lead candidate selection expected in H1 2026 and an update at AACR 2026[99, 140] Financial Outlook - The company's cash of approximately USD 116 million (CHF 93 million) ensures funding until 2028[99]

Core Insights - Molecular Partners AG is advancing its clinical-stage pipeline of DARPin therapeutics, focusing on targeted radiotherapy and immune cell engagers, with significant milestones expected in 2026 [1][20]. Financial Overview - As of December 31, 2025, the company reported cash and cash equivalents of CHF 93.1 million, sufficient to fund operations until 2028 [3]. Clinical Development Updates - The Phase 1/2a trial for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer (SCLC), has commenced, with initial patient dosing expected in Q1 2026 and initial clinical data anticipated in the same year [2][4][7]. - MP0726, another Radio-DARPin targeting mesothelin (MSLN) for ovarian cancer, is also in development, with preclinical data presented at the 2025 SNMMI meeting [6]. - An investigator-initiated Phase 2 trial for MP0317 in cholangiocarcinoma is ongoing, with the first patient treated in early 2026 [10][11]. - MP0533, a tetra-specific T cell engager for acute myeloid leukemia (AML), is in a Phase 1/2a trial, with updates on its clinical development expected in H1 2026 [12][14]. Scientific Advisory Board - The formation of a scientific advisory board, chaired by Prof. Ken Herrmann, aims to accelerate the development of targeted radiotherapeutics [8]. DARPin Technology - Molecular Partners' DARPin therapeutics are designed for high specificity and stability, enabling effective delivery of radioactive payloads to tumors while minimizing damage to healthy tissues [19].

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs aimed at addressing medical challenges that other drug modalities cannot effectively tackle [3] Group 1: Company Overview - Molecular Partners AG is listed on both SIX and NASDAQ under the ticker MOLN and was founded in 2004 [3] - The company has its headquarters in Zurich, Switzerland, and an office in Concord, Massachusetts, USA [3] - The primary focus of the company is oncology, with various programs in different stages of pre-clinical and clinical development [3] Group 2: Upcoming Events - The CEO, Patrick Amstutz, will present the latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2025, from 10:30 AM to 11:10 AM PT [2] - A webcast of the presentation will be available on the Molecular Partners website under the Events tab [2] Group 3: Strategic Partnerships - Molecular Partners collaborates with leading pharmaceutical companies to leverage the advantages of DARPins and provide unique solutions to patients [3]

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs aimed at addressing medical challenges that other drug modalities cannot effectively tackle [3] Group 1: Company Overview - Molecular Partners AG is pioneering the design and development of DARPin therapeutics, with a primary focus on oncology [3] - The company has various programs in different stages of pre-clinical and clinical development [3] - Founded in 2004, Molecular Partners has offices in Zurich, Switzerland, and Concord, Massachusetts, USA [3] Group 2: Upcoming Presentation - The CEO, Patrick Amstutz, will present the company's latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2025 [2] - The presentation will take place from 10:30 AM to 11:10 AM PT at the Westin St. Francis in San Francisco, CA [2] - A webcast of the presentation will be available on the Molecular Partners website [2]

Core Insights - Molecular Partners AG is presenting updated data from a Phase 1/2a trial of its T-cell engager MP0533 for treating acute myeloid leukemia (AML) at the 67th ASH Annual Meeting [1][2] Group 1: Trial Results - The multicenter, open-label study shows that densified dosing of MP0533 is tolerable and leads to improved serum exposure with preliminary antitumor activity [2][4] - As of September 1, 2025, 54 patients have been treated with MP0533, with 8 out of 48 evaluable patients achieving a response, including 5 reaching composite complete responses [4] - Six of the eight responders had less than 20% bone marrow blasts at baseline, indicating that patients with low disease burden are likely to benefit the most from MP0533 [4][7] Group 2: Expert Commentary - Prof. Courtney DiNardo expressed optimism about the clinical benefits of MP0533 in mutation-agnostic R/R AML patients, particularly those with lower disease burden, supporting further investigation in a Phase 2 setting [3][5] Group 3: Drug Mechanism and Design - MP0533 is a novel tetra-specific T cell-engaging DARPin that targets three tumor-associated antigens (CD33, CD123, CD70) on AML cells and the immune activator CD3 on T cells, designed to preferentially kill AML cells while minimizing damage to healthy cells [6][9] Group 4: Future Development - The trial is progressing well, with the densified dosing regimen showing feasibility and an acceptable safety profile, prompting interest from several consortia for further studies in both R/R and front-line AML settings [5][9]

Core Insights - Molecular Partners AG presented new data on MP0712, a Radio-DARPin targeting DLL3, at the Targeted Radiopharmaceuticals Summit Europe, showcasing promising human imaging results and supporting mechanism of action data [1][2][3] Clinical Development - MP0712 is being developed in collaboration with Orano Med for treating small cell lung cancer (SCLC) and other neuroendocrine cancers, with a Phase 1 trial expected to start by the end of 2025 [1][7] - The Phase 1 Investigational New Drug (IND) application has been filed, and ongoing discussions with the FDA are taking place [7][8] Imaging and Efficacy - Initial imaging results indicate targeted delivery of MP0712 into tumors with minimal exposure to healthy organs, suggesting its potential effectiveness in a clinical setting [2][3] - A case study showed specific uptake in tumor lesions at 24 hours, sustained over four days, with limited accumulation in healthy organs [3][5] Mechanism of Action - MP0712 is engineered for half-life optimization to maintain drug levels in the blood, supporting its intended mechanism of action [3][6] - The data suggests that MP0712 can achieve high tumor uptake even with low DLL3 expression levels, leveraging internalization and optimal binding properties [6] Future Outlook - The company anticipates initial clinical data from the Phase 1/2a study in 2026, which will assess safety and determine a recommended phase 2 dose for MP0712 [7][8] - Molecular Partners is also advancing additional Radio-DARPin programs in 2026 [2][8] Technology and Innovation - The Radio-DARPin platform combines the targeting capabilities of DARPins with the therapeutic potential of 212Pb, aiming to improve the delivery of radioactive payloads to solid tumors [11] - DARPins are designed to offer high specificity and affinity, making them suitable for efficient delivery of therapeutic radionuclides [12]